title: A patient with AL amyloidosis with negative free light chain results.
abstract: The detection and quantification of amyloidogenic monoclonal light chains are necessary for the diagnosis and evaluation of response to treatment in AL amyloidosis. However, the amyloid clone is often small and difficult to detect. We report the case of a 68-year-old man who was referred to our Center in April 2013 after syncope and the identification of left ventricular hypertrophy at echocardiography, suspected for amyloidosis. A commercial agarose gel electrophoresis immunofixation (IFE) did not reveal monoclonal components in serum and urine. The κ serum free light chain (FLC) concentration was 21.5 mg/L, λ 33 mg/L (κ/λ ratio 0.65), NT-proBNP 9074 ng/L (u.r.l. <332 ng/L) and an echocardiogram confirmed characteristic features of amyloidosis. The abdominal fat aspiration was positive and the amyloid typing by immune-electron microscopy revealed λ light chains deposits. A high-resolution (hr) IFE of serum and urine showed a faint monoclonal λ component in the urine. A bone marrow biopsy showed 8% plasma cells (BMPC) and a kappa/lambda light-chain restriction with λ light chain on immunofluorescence. The diagnosis of AL (λ) amyloidosis with cardiac involvement was made. In May 2013, patient was started on cyclophosphamide, bortezomib and dexamethasone. After six cycles, serum and urine hr-IFE were negative, the bone marrow biopsy showed 3% BMPC without light chain restriction by immunofluorescence, and a decrease of NT-proBNP was observed (5802 ng/L).Thus, treatment was discontinued. In this patient the amyloid clone could be detected only by in house hr-IFE of urine and bone marrow examination. The detection of the small dangerous amyloidogenic clone should be pursued with a combination of high-sensitivity techniques, including assessment of BMPC clonality. Studies of novel tools, such as mass spectrometry on serum and next-generation flow cytometry analysis of the bone marrow, for detecting plasma cell clones in AL amyloidosis and other monoclonal light chain-related disorders are warranted.
authors.forename: Paolo
authors.initials: P
authors.lastname: Milani
authors.forename: Veronica
authors.initials: V
authors.lastname: Valentini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ferraro
authors.forename: Marco
authors.initials: M
authors.lastname: Basset
authors.forename: Francesca
authors.initials: F
authors.lastname: Russo
authors.forename: Andrea
authors.initials: A
authors.lastname: Foli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Palladini
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Merlini
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000097:blood / Q000175:diagnosis* / Q000473:pathology / Q000652:urine; D004587:Electrophoresis, Agar Gel; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis; D007122:Immunoelectrophoresis; D007145:Immunoglobulin kappa-Chains / Q000032:analysis*; D007146:Immunoglobulin lambda-Chains / Q000032:analysis*; D008297:Male; D010950:Plasma Cells / Q000473:pathology; D013575:Syncope / Q000175:diagnosis
chemical_list: D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains